Phase I/II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion

NCT06439485 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Advanced Cholangiocarcinoma
FGFR2 Fusion

Interventions

DRUG: Pemigatinib
DRUG: Atezolizumab
DRUG: Bevacizumab

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]
[object Object]